Osimertinib (Tagrisso)

Ingredients: Osimertinib
Dosage Form: Oral tablets
Innovator’s Brand Name: Tagrisso
Generic Brand Name: Osikin
Generic Manufacturer: Ziska Pharma

Indications:
Osimertinib is indicated for the treatment of metastatic non‑small cell lung cancer in patients whose tumors harbor epidermal growth factor receptor (EGFR) exon 19 deletions, exon 21 (L858R) substitutions, or T790M mutations. It may be used as first‑line therapy or in patients with disease progression following prior EGFR tyrosine kinase inhibitor therapy.

Dosage and Administration:
The recommended dose is 80 mg orally once daily, with or without food. Tablets may be dispersed in a small amount of non‑carbonated water for administration but should not be crushed, heated, or sonicated. If a dose is missed, take the next scheduled dose at its regular time; do not double the dose.

Adverse Reactions:
Common adverse reactions include diarrhea, rash, dry skin, nail disorders, stomatitis, fatigue, and decreased appetite.

Storage:
Store in a cool, dry place below 30 °C, protected from moisture and light, and keep out of reach of children.

Package Insert (Prescribing Information):

Download Link